Risk minimization of JAK inhibitors in ulcerative colitis following regulatory guidance
Silvio Danese, Virginia Solitano, Vipul Jairath, Laurent Peyrin‐Biroulet
Topics & Concepts
MedicineTofacitinibJanus kinaseUlcerative colitisUnintended consequencesIntensive care medicineRisk analysis (engineering)Agency (philosophy)Regulatory agencyPharmacologyInternal medicineDiseaseEpistemologyPolitical sciencePhilosophyLawRheumatoid arthritisPublic administrationCytokineInflammatory Bowel DiseaseCytokine Signaling Pathways and InteractionsHealth Systems, Economic Evaluations, Quality of Life